Company Overview and News

 
New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab

2018-10-19 globenewswire
SALT LAKE CITY, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra® that evaluated the test’s ability to track treatment response in patients with rheumatoid arthritis (RA). The studies were conducted by academic collaborators and will be presented at the American College of Rheumatology meeting in Chicago, IL.
MYGN

6
Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?

2018-10-17 zacks
Quest Diagnostics (DGX - Free Report) is scheduled to report third-quarter 2018 earnings before the opening bell on Oct 23.
TMO DGX MYGN BAX UNH

 
FDA Approves Pfizer’s Talzenna for Breast Cancer

2018-10-17 biospace
The U.S. Food and Drug Administration (FDA) approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.
MYGN BMRN CLVS

1
UPDATE 1-FDA approves Pfizer's drug for advanced breast cancer

2018-10-16 reuters
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc’s drug for an advanced form of breast cancer tied to an inherited gene mutation.
PFZ MYGN 500680 PFE PFIZER

1
FDA approves Pfizer's breast cancer drug

2018-10-16 channelnewsasia
The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc's drug for advanced form of breast cancer.
PFZ MYGN 500680 PFE PFIZER

 
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Pfizer’s TALZENNA® (talazoparib)

2018-10-16 globenewswire
SALT LAKE CITY, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib).
MYGN

2
Monthly NAV Update for September 2018

2018-10-16 globenewswire
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS
AIZ NBPE MYGN LNSTY NBPVF NBPZ

 
MYGN / Myriad Genetics, Inc. FORM 8-K/A (Current Report)

2018-10-15 sec.gov
Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
MYGN

4
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus

2018-10-11 zacks
Myriad Genetics recently signed a commercialization plan with Pfizer Inc. (PFE - Free Report) for FDA approval to use its BRACAnalysis CDx as a companion diagnostic with the latter’s talazoparib. Meanwhile, Thermo Fisher Scientific Inc. (TMO - Free Report) announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker. In fact, there are many similar developments that clearly point toward the rapid emergence of molecular diagnostics in the MedTech space.
PFZ TMO LMNX MYGN 500680 PFE PFIZER GHDX

24
Market Snapshot: S&P 500 on track for longest losing streak in roughly 2 years as tech stocks retreat

2018-10-10 marketwatch
U.S. stocks slumped Wednesday, with major indexes breaching key support levels and extending their downward spiral, as rising bond yields continued to weigh on market sentiment.
SHLD PFZ IMPV TWTR AAPL MYGN SBUX SHLDW MSFT 500680 PFE PFIZER

1
Myriad Genetics shares soar 7% on news it will conduct testing for Pfizer breast cancer treatment

2018-10-10 marketwatch
Shares of Myriad Genetics Inc. MYGN, +7.32% soared 7% Wednesday in a down market, after it announced an agreement to carry out testing for Pfizer Inc. PFE, -0.45% of a treatment for breast cancer. The Salt Lake City, Utah-based company said it will provide BRACAnalysis testing in a mid-stage trial of talazoparib, Pfizer's treatment for "triple negative breast cancer." Myriad specializes in testing hereditary cancers.
PFZ MYGN 500680 PFE PFIZER

 
MYGN / Myriad Genetics, Inc. DEF 14A

2018-10-10 sec.gov
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MYGN

 
MYGN / Myriad Genetics, Inc. DEFA14A

2018-10-10 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MYGN

1
Myriad and Pfizer Build Upon a Previously Announced Companion Diagnostic Agreement

2018-10-09 globenewswire
SALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that it has signed a commercialization plan with Pfizer Inc. The plan is under an existing companion diagnostic agreement, in which Myriad is pursuing U.S. Food and Drug Administration (FDA) approval for its BRACAnalysis CDx® to be used as a companion diagnostic with Pfizer’s investigational PARP (poly ADP ribose polymerase) inhibitor, talazoparib.
PFZ MYGN 500680 PFE PFIZER

4
Guardant IPO: 97.4% Y/Y Revenue Growth And Seems Undervalued

2018-10-03 seekingalpha
Guardant health Inc. is a precision oncology company focused on advanced analytics of molecular information throughout all stages of the disease.
TMO DGX MYGN FMI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MYGN / Myriad Genetics, Inc. on message board site Silicon Investor.

Myriad Genetics, Inc. (MYGN) Myriad Genetics, Inc. (MYGN) Myriad Genetics, Inc. (MYGN) MYGN MYGN MYGN
CUSIP: 62855J104